Fig. 1. Efficacy of incretin hormones—glycosylated hemoglobin (HbA1c) change from baseline. LR, liraglutide; SM, semaglutide; TZP, tirzepatide. LR 0.6 mg, 1.2 mg, and 1.8 mg (LEAD2 study
66); LR 3.0 mg (SCALE study
13); SM 0.5 mg and 1.0 mg (SUSTAIN 1 study
67); SM 2.4 mg (STEP2 study
12); TZP 5 mg, 10 mg, and 15 mg (SURPASS 1 study
14).